Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study., PMID:40055759
Interleukin 6 inhibition in refractory antisynthetase syndrome: case-based literature review., PMID:40053413
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)., PMID:40044198
Nontraumatic terminal ileal perforation in a patient with resistant palindromic rheumatism treated with sarilumab: A case report., PMID:40024808
Effectiveness of baricitinib versus sarilumab on disease activity in patients with RA: a propensity score matching study., PMID:39959132
Successful Remission of Refractory Rheumatoid Pleural Effusion and Arthritis Using Sarilumab: A Case Report., PMID:39744302
Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review., PMID:39711360
Rates of glucocorticoid taper in the management of polymyalgia rheumatica: the science behind the "art"., PMID:39641835
A Glimpse for the subsistence from pandemic SARS-CoV-2 infection., PMID:39603070
Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies., PMID:39563277
Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review and meta-analysis., PMID:39221116
[Polymyalgia rheumatica: What's new?]., PMID:39146754
Use of interleukin-6 receptor antibodies in the second and third trimester of pregnancy: a retrospective cohort study., PMID:39116898
Newer Therapies in Rheumatology., PMID:39084836
The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study., PMID:39073577
Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials., PMID:39073574
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study., PMID:39049740
Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized COVID-19 patients., PMID:39028068
Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study., PMID:38804962
Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection., PMID:38795859
Late Tuberculosis Reactivation After Severe Covid-19., PMID:38715882
Sarilumab (Kevzara) for polymyalgia rheumatica., PMID:38696312
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study., PMID:38452297
Structural insights into IL-6 signaling inhibition by therapeutic antibodies., PMID:38393945
[Sarilumab for polymyalgia rheumatica]., PMID:38240818
Two cases of dermatomyositis associated with neuroendocrine tumors., PMID:38187177
Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry., PMID:38182801
Treatment experiences with focus on IL-6R inhibition in patients with VEXAS syndrome and a case of remission with azacytidine treatment., PMID:38141211
Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases., PMID:38056919
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?, PMID:37989892
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper., PMID:37792612
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)., PMID:37696589
Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI)., PMID:37606691
Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis., PMID:37566157
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis., PMID:37471590
Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry., PMID:37349636
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events., PMID:37328287
Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance., PMID:37300807
Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris., PMID:37146158
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients., PMID:37055774
Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab., PMID:36858816
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis., PMID:36727470
Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials., PMID:36607422
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab., PMID:36413080
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®)., PMID:36401769
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials., PMID:36254081
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce., PMID:36150213
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors., PMID:36148395
Immune-related adverse events of biological immunotherapies used in COVID-19., PMID:36091800
Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents., PMID:36064423
For research use only. Not for human or drug use.
